■太阳荨麻疹(SU),一种相对罕见的皮肤炎症和光敏疾病,通常对标准荨麻疹治疗有抵抗力。尚未广泛探索SU患者的生活质量(QOL)。进行这项研究是为了阐明治疗的临床特征和有效性(例如,硬化疗法)用于SU并确定SU患者的生活质量。
■作者检查了这些特征,治疗,使用病历和问卷方法对29名日本SU患者的QOL状况进行了调查。
■在29名患者中,H1抗组胺治疗(H1)对22例(75.8%)患者有效。H2抗组胺疗法(H2)在7例患者中有3例(42.9%)有效。紫外线A(UVA)硬化疗法在9例患者中有8例(88.9%)有效。3例患者中有3例可见光(VL)硬化治疗无效。在一名同时接受UVA和VL硬化治疗的患者中,只有UVA硬化治疗有效.在调查问卷中,与疾病发作相比,18例患者(90%)报告有一些改善(4例完全缓解,尽管症状持续轻微,但仍有6人完成了治疗,八人正在接受中度症状的治疗),而两名患者报告恶化。完全缓解患者的平均病程为4年,而未缓解的患者的平均病程为8.8年.当前状态的平均皮肤病生活质量指数(DLQI)评分为7.4。DLQI与症状/治疗状态之间存在相关性。然而,DLQI和作用谱以及DLQI和治疗均未表现出显着差异。
■问卷显示了SU患者的当前生活质量状况和长期预后。与疾病发作相比,在本研究评估时,大多数患者表现出改善.所有SU患者应同时尝试H1和H2。UVA硬化疗法可能是具有包括UVA的作用谱的SU患者的一种选择。
UNASSIGNED: Solar urticaria (SU), a relatively rare skin inflammatory and photosensitivity disease, is often resistant to standard urticaria treatment. Quality of life (QOL) among SU patients has not been extensively explored. This study was performed to clarify the clinical features and effectiveness of therapies (e.g., hardening therapy) for SU and to determine QOL among SU patients.
UNASSIGNED: The authors examined the characteristics, treatments, and QOL statuses of 29 Japanese SU patients using medical records and a questionnaire approach.
UNASSIGNED: Among 29 patients, H1 antihistamine therapy (H1) was effective in 22 (75.8%) patients. H2 antihistamine therapy (H2) was effective in three of seven (42.9%) patients. Ultraviolet radiation A (
UVA) hardening therapy was effective in eight of nine (88.9%) patients. Visible light (VL) hardening therapy was ineffective in three of three patients. In one patient who underwent both
UVA and VL hardening therapy, only
UVA hardening therapy was effective. In the questionnaire, 18 patients (90%) reported some improvement compared with disease onset (four had complete remission, six had completed treatment although mild symptoms persisted, and eight were receiving treatment with moderate symptoms), whereas two patients reported exacerbation. Patients in complete remission had a mean disease duration of 4 years, whereas patients not in remission had a mean disease duration of 8.8 years. The mean Dermatology Life Quality Index (DLQI) score for the current status was 7.4. There was a correlation between DLQI and symptom/treatment status. However, neither DLQI and action spectra nor DLQI and treatments exhibited significant differences.
UNASSIGNED: The questionnaire revealed current QOL status and long-term prognosis in SU patients. Compared with disease onset, most patients showed improvement when assessed for this study. Both H1 and H2 should be attempted for all SU patients.
UVA hardening therapy may be an option for SU patients with an action spectrum that includes
UVA.